Viatris Inc. (VTRS) announced that it has entered into definitive agreements with Biocon Limited for the sale of its equity stake in Biocon Biologics Limited. Under the agreements, Biocon will acquire all of Viatris' convertible preferred equity in Biocon Biologics for a total consideration of $815 million, comprised of $400 million in cash and $415 million in newly issued equity shares of Biocon.
Viatris will sell its equity stake in Biocon Biologics to Biocon for $400 million in cash and $415 million in equity shares of Biocon Limited. The newly issued shares will be listed and traded on the National Stock Exchange of India and are subject to a six-month lock-up period.
The agreements accelerate the expiration of biosimilars non-compete restrictions previously placed on Viatris in 2022. These restrictions will expire immediately upon closing for all ex-U.S. markets and in November 2026 for U.S. markets.
The transaction is expected to close in the first quarter of 2026, subject to customary closing conditions.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.